Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

PROCEDURE3 trials

Sponsors

Stanford University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)Lymphoma, B-cellLymphoma, Non-HodgkinMalignant Lymphoma, Non-HodgkinPh+ ALL

Phase 2

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

TerminatedNCT00481832

Stanford UniversityLymphoma, Non-Hodgkin

Start: 2007-01-31End: 2017-03-30Updated: 2018-02-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

TerminatedNCT00482053

Stanford UniversityDiffuse Large B-cell Lymphoma (DLBCL), Lymphoma, B-cell, Lymphoma, Non-Hodgkin +1

Start: 2006-10-31End: 2010-05-31Updated: 2018-05-14

Unknown Phase

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

Not yet recruitingNCT07493161

Institute of Hematology & Blood Diseases Hospital, ChinaPh+ ALL

Start: 2026-04-01End: 2030-03-30Target: 100Updated: 2026-03-25